Interleukin-18 Binding Protein (IL-18BP): A Long Journey From Discovery to Clinical Application
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
IL-18 binding protein (IL-18BP) was originally discovered in 1999 while attempting to identify an IL-18 receptor ligand binding chain (also known as IL-18Rα) by subjecting concentrated human urine to an IL-18 ligand affinity column. The IL-18 ligand chromatography purified molecule was analyzed by protein microsequencing. The result revealed a novel 40 amino acid polypeptide. To isolate the complete open reading frame (ORF), various human and mouse cDNA libraries were screened using cDNA probe derived from the novel IL-18 affinity column bound molecule. The identified entire ORF gene was thought to be an IL-18Rα gene. However, IL-18BP has been proven to be a unique soluble antagonist that shares homology with a variety of viral proteins that are distinct from the IL-18Rα and IL-18Rβ chains. The IL-18BP cDNA was used to generate recombinant IL-18BP (rIL-18BP), which was indispensable for characterizing the role of IL-18BP in vitro and in vivo. Mammalian cell lines were used to produce rIL-18BP due to its glycosylation-dependent activity of IL-18BP (approximately 20 kDa). Various forms of rIL-18BP, intact, C-terminal his-tag, and Fc fusion proteins were produced for in vitro and in vivo experiments. Data showed potent neutralization of IL-18 activity, which seems promising for clinical application in immune diseases involving IL-18. However, it was a long journey from discovery to clinical use although there have been various clinical trials since IL-18BP was discovered in 1999. This review primarily covers the discovery of IL-18BP along with how basic research influences the clinical development of IL-18BP.
Abstract
IL-18 binding protein (IL-18BP) was originally discovered in 1999 while attempting to identify an IL-18 receptor ligand binding chain (also known as IL-18Rα) by subjecting concentrated human urine to an IL-18 ligand affinity column. The IL-18 ligand chromatography purified molecule was analyzed by protein microsequencing. The result revealed a novel 40 amino acid polypeptide. To isolate the complete open reading frame (ORF), various human and mouse cDNA libraries were screened using cDNA probe derived from the novel IL-18 affinity column bound molecule. The identified entire ORF gene was thought to be an IL-18Rα gene. However, IL-18BP has been proven to be a unique soluble antagonist that shares homology with a variety of viral proteins that are distinct from the IL-18Rα and IL-18Rβ chains. The IL-18BP cDNA was used to generate recombinant IL-18BP (rIL-18BP), which was indispensable for characterizing the role of IL-18BP in vitro and in vivo. Mammalian cell lines were used to produce rIL-18BP due to its glycosylation-dependent activity of IL-18BP (approximately 20 kDa). Various forms of rIL-18BP, intact, C-terminal his-tag, and Fc fusion proteins were produced for in vitro and in vivo experiments. Data showed potent neutralization of IL-18 activity, which seems promising for clinical application in immune diseases involving IL-18. However, it was a long journey from discovery to clinical use although there have been various clinical trials since IL-18BP was discovered in 1999. This review primarily covers the discovery of IL-18BP along with how basic research influences the clinical development of IL-18BP.
참고문헌 (20)
- Novick D, "Interleukin-18 binding protein : a novel modulator of the Th1 cytokine response", Immunity, 10, pp.127~136 (1999)
- Matsudaira P, "Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes", J Biol Chem, 262, pp.10035~10038 (1987)
- Novick D, "Soluble cytokine receptors are present in normal human urine", J Exp Med, 170, pp.1409~1414 (1989)
- Novick D, "The human interferon alpha", beta receptor : characterization and molecular cloning, 1994, pp.77, 391~400
- Novick D, "Proteinase 3 is an IL-32 binding protein", Proc Natl Acad Sci U S A, 103, pp.3316~3321 (2006)
- Xiang Y, "IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins", Proc Natl Acad Sci U S A, 96, pp.11537~11542 (1999)
- Hoshino K, "Cutting edge : generation of IL-18 receptor-deficient mice : evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor", J Immunol, 162, pp.5041~5044 (1999)
- Kim SH, "Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18", Proc Natl Acad Sci U S A, 97, pp.1190~1195 (2000)
- Kim M, "Lessons from the success and failure of targeted drugs for rheumatoid arthritis : perspectives for effective basic and translational research", Immune Netw, 22, pp.e8~ (2022)
- Marks KE, "Toll-like receptor 2 in autoimmune inflammation", Immune Netw, 21, pp.e18~ (2021)
- Akkaya I, "NLRC4 inflammasome-mediated regulation of eosinophilic functions", Immune Netw, 21, pp.e42~ (2021)
- Ham J, "Targeting the epithelium-derived innate cytokines : from bench to bedside", Immune Netw, 22, pp.e11~ (2022)
- Nowarski R, "Epithelial IL-18 equilibrium controls barrier function in colitis", Cell, 163, pp.1444~1456 (2015)
- Jarret A, "Enteric nervous system-derived IL-18 orchestrates mucosal barrier immunity", Cell, 180, pp.813~814 (2020)
- Zhou T, "IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy", Nature, 583, pp.609~614 (2020)
- Gabay C, "Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa(IL-18BP)in adult-onset Still’s disease", Ann Rheum Dis, 77, pp.840~847 (2018)
- Canna S, "A157 : Macrophage activation syndrome-like illness due to an activating mutation in NLRC4", Arthritis Rheumatol, 66, pp.S203~ (2014)
- Canna SW, "An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome", Nat Genet, 46, pp.1140~1146 (2014)
- Romberg N, "Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation", Nat Genet, 46, pp.1135~1139 (2014)
- Canna SW, "Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition", J Allergy Clin Immunol, 139, pp.1698~1701 (2017)